Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada

• Главные авторы: Kohli Michele (Автор), Lawrence Donna (Автор), Haig Jennifer (Автор), Anonychuk Andrea (Автор), Demarteau Nadia (Автор)
• Формат: ‌
• Опубликовано: BMC, 2012-10-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

<p>Background</p> <p>In Canada, two vaccines that have demonstrated high efficacy against infection with human papillomavirus (HPV) types −16 and −18 are available. The HPV-6/11/16/18 vaccine provides protection against genital warts (GW) while the HPV-16/18 vaccine may provide bet...